The article by Candia et al1 represents an important installment in a rapidly evolving story. Topical glucocorticoids administered several times daily can cause a significant increase in intraocular pressure (IOP) in about one-third of the general population, with a rather substantial increase (>15 mm Hg) in about 5%.2,3 Most patients with primary open-angle glaucoma (POAG), their first-order blood relatives, and persons with diabetes mellitus also have a strong ocular hypertensive response to topical glucocorticoids.4,5 There is reasonable evidence that if treated long enough, all humans will exhibit at least some IOP increase.